More about West Pharmaceutical Services, Inc.
Regulatory Filings for West Pharmaceutical Services, Inc.
Fundamentals for West Pharmaceutical Services, Inc.
The Fed Study Revealing Tomorrow's Investment Themes
America’s Empty Offices Hit Pensions Hard
Rural Hospitals Buckle Under Private Equity
Fake Brokers, Spoofed GPS: Who Pays for Cargo Crime?
Fundamentals for West Pharmaceutical Services, Inc.
Business Operations:
Sector: HealthcareIndustry: Medical Instruments & Supplies
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Revenue projections:
WST is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.
Financial Ratios:
| currentRatio | 2.710000 |
|---|---|
| forwardPE | 33.790382 |
| debtToEquity | 10.734000 |
| earningsGrowth | 0.561000 |
| revenueGrowth | 0.210000 |
| grossMargins | 0.362780 |
| operatingMargins | 0.216950 |
| trailingEps | 7.490000 |
| forwardEps | 9.553310 |
WST's current ratio is 2.71, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting WST has no trouble covering its short-term financial obligations.
WST's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
WST's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for WST.
WST's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
WST's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in WST's earnings potential, suggesting stronger financial performance compared to the previous year.
Price projections:
The stock price of WST has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.
Insider Transactions:
Recent trading of WST stock saw 1 sales, with market price at 302.20001220703125 per share.No sell transactions were carried out during the period under review.With more buys than sells around WST's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.
Recommendation changes over time:
Analysts' recent buy bias toward WST suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see WST as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
Crypto’s $2.4T Reality Check in 2026
The Machines That Ate the Grid: Five Centuries of Power Hunger
Private Credit’s Secret Banking Backbone Is Growing Faster Than Anyone Expected